Zhang Yan, Li Wancheng, Niu Jubao, Fan Zeyang, Li Xin, Zhang Hui
The Second Clinical Medical School, Lanzhou University, Lanzhou, China.
Department of General Surgery, The Second Hospital of Lanzhou University, The Second Clinical Medical School, Lanzhou University, Lanzhou, China.
Front Immunol. 2025 Jun 24;16:1586959. doi: 10.3389/fimmu.2025.1586959. eCollection 2025.
As a typical pathological feature of pancreatic ductal adenocarcinoma, reprogramming of glucose metabolism synergistically drives the tumorigenesis and development process through molecular mechanisms such as regulating the expression of driver genes, modifying key functional proteins, triggering mitochondrial metabolism abnormality, and remodeling the tumor microenvironment. It is worth noting that this metabolic remodeling phenomenon is significantly associated with the formation of chemoresistance. Based on the latest research progress, this paper systematically describes the molecular basis of glucose metabolic reprogramming in pancreatic cancer, drug resistance characteristics and its targeted intervention strategies, and provides a theoretical framework for the research and development of innovative drugs.
作为胰腺导管腺癌的典型病理特征，葡萄糖代谢重编程通过调节驱动基因表达、修饰关键功能蛋白、引发线粒体代谢异常以及重塑肿瘤微环境等分子机制，协同驱动肿瘤发生和发展过程。值得注意的是，这种代谢重塑现象与化疗耐药的形成显著相关。基于最新研究进展，本文系统阐述了胰腺癌中葡萄糖代谢重编程的分子基础、耐药特征及其靶向干预策略，为创新药物研发提供理论框架。
